Celera Seeks Approval For Coronary Heart Disease Genoytyping Assay
This article was originally published in The Gray Sheet
Executive Summary
Celera is seeking FDA approval for a genetic assay to detect risk of coronary heart disease, including potential use as a therapy guide for the 20-30 million Americans who are being considered for treatment with statin drugs such as Lipitor.
You may also be interested in...
Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.
Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase
Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.
News In Brief
Quest Diagnostics buys Celera